Osaic Holdings
RAPP

Osaic Holdings’s Rapport Therapeutics RAPP Stock Holding History

Osaic Holdings’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.17K Buy
124
+8
+7% +$294 ﹤0.01% 6919
2026
Q1 		$3.63K Buy
116
+107
+1,189% +$3.01K ﹤0.01% 6829
2025
Q4 		$273 Buy
+9
New +$249 ﹤0.01% 7537

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Osaic Holdings's RAPP Position: Q2 2026 in Review

Osaic Holdings increased its Rapport Therapeutics (RAPP) stake by 6.9% in Q2 2026, buying an estimated $294 and bringing the position to 124 shares worth $5.17K. The position accounts for ﹤0.01% of the portfolio, ranked #6919.

Osaic Holdings first reported a position in RAPP in Q4 2025 and has held it in 3 quarters since. 160 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Osaic Holdings held 124 shares of Rapport Therapeutics worth $5.17K as of Q2 2026.
  • Osaic Holdings bought 8 Rapport Therapeutics shares in Q2 2026, an estimated $294.
  • Rapport Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #6919 holding.
  • Osaic Holdings first reported a position in Rapport Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 160 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.